Last reviewed · How we verify
Dexamphetamine
Dexamphetamine, marketed by The Netherlands Cancer Institute, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. A key strength of Dexamphetamine is its established market presence, leveraging the credibility of The Netherlands Cancer Institute. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Dexamphetamine |
|---|---|
| Also known as | Dextroamphetamine, Aspen Dexamfetamine Tablets |
| Sponsor | The Netherlands Cancer Institute |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder (PHASE2)
- A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (PHASE1)
- Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users (PHASE2)
- Pharmacological and Behavioral Treatment After Bariatric Surgery: Medication Change for Non-Responders (Stage 2b) (PHASE2, PHASE3)
- Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression (PHASE2)
- Vyvanse in Children Aged 6 to 12 Years (EARLY_PHASE1)
- Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment (PHASE3)
- Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamphetamine CI brief — competitive landscape report
- Dexamphetamine updates RSS · CI watch RSS
- The Netherlands Cancer Institute portfolio CI